Navigation Links
Accera, Inc. to Present Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting

BROOMFIELD, Colo., April 24, 2007 /PRNewswire/ -- Accera Inc. announced today that topline data from its Phase IIb study of its lead compound AC-1202 in Alzheimer's disease (AD) will be presented at the annual meeting of the American Academy of Neurology (AAN) in Boston. Judged by the AAN to be in the top five percent of the program, the data will also be featured in the Scientific Highlights Plenary Session.

Accera's vice president of clinical development Dr. Lauren Costantini will present the abstract, "Clinical Efficacy of AC-1202 in Mild to Moderate Alzheimer's Disease" at the Late Breaking Science session on Tuesday, May 1 at 3:45 p.m. EDT. The plenary session will be held at 5:15 p.m. EDT on Friday, May 4.

The randomized, double-blinded, placebo-controlled Phase II trial evaluated 152 subjects that had previously been diagnosed with mild to moderate AD. Subjects visited the clinic on five occasions during the study to have their memory and other symptoms evaluated. Treatment lasted for three months and following a two-week washout, all subjects who had completed the three-month study were given the opportunity to participate in an open-label extension study. The open-label data will be presented at the Alzheimer's Association's International Prevention Conference in Washington, DC in early June.

About AC-1202

AC-1202 is an orally available, liquid compound that has been shown in preclinical studies to prevent the massive brain cell death seen in AD and other neurodegenerative diseases. Brain imaging techniques performed on AD patients reveal a decreased uptake of glucose, the brain's preferred source of energy. Efficiently converted by the liver into ketones, AC-1202 preserves the glucose-deprived brain cells with an alternative energy source. The potentially neuroprotective mechanism of AC-1202 is also being evaluated in age-associated memory impairment, Parkinson's disease, F riedrich's ataxia, and canine cognitive dysfunction.

About Accera, Inc.

Based in Broomfield, CO, Accera, Inc. is a privately held biopharmaceutical company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, AC-1202, is a first- in-class molecule currently in Phase II clinical trials for Alzheimer's disease and age-associated memory impairment. A key element of Accera's strategy is to develop AC-1202 and other small molecule compounds in its pipeline with corporate partners for a range of memory and cognition disorders associated with neurological conditions and aging. www.accerapharma.com

    For information contact:

    Meghan Feeks

    Richard Lewis Communications, Inc.

    212-827-0020

    

mfeeks@rlcinc.com

CONTACT: Meghan Feeks of Richard Lewis Communications, Inc.,+1-212-827-0020, or , for Accera, Inc. mfeeks@rlcinc.com

Web site: http://www.accerapharma.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
2. Accera, Inc. Announces Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... , April 18, 2017 Research and ... Market 2017-2021" report to their offering. ... The global arthroscopy devices market to grow at a ... report, Global Arthroscopy Devices Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017 /PRNewswire/ ... results of collaboration started in 2016, in which ... "Artificial Brain SOINN". The companies achieved initial results ... ultrasound solution by Artificial Brain SOINN. The results ... Tokyo Big Sight, April 19-21, at booths 4505 ...
(Date:4/18/2017)... , April 18, 2017 Recursion ... biological science with machine learning techniques to discover treatments ... Dr. Yolanda Chong as vice president of ... Johnson & Johnson in Belgium , ... that focused on applying high-dimensional biological approaches to the ...
Breaking Medicine Technology:
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... “The Saint ... Saint with Trin, and Omega Station” is the creation of published author, Chris Jackson. ... Dallas Metroplex where he works in the Dallas Independent School District teaching English. He ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, a pre-clinical stage ... the treatment of Acute Ischemic Stroke (AIS), today announced it has appointed Creganna ... advances towards regulatory and clinical phases. , "This is another important step for ...
(Date:4/22/2017)... ... April 22, 2017 , ... Ecommerce sales have grown every year since ... $394.9 billion. The consequences of rapid innovation and growth are often neglected in ... it is every business and individual’s job to give something back to the planet ...
(Date:4/22/2017)... ... ... San Juan Capistrano summer camp team at the Boys and Girls Club of ... to provide physical activities for all campers. To read the report, click here ... increase in specialty camps that focus on what the report terms as “sitting subjects” like ...
(Date:4/21/2017)... Boston, MA (PRWEB) , ... April 21, 2017 ... ... Boston University professor Christopher Salas-Wright finds that youth violence is declining—and at noteworthy ... in the relative proportion of young people involved in violence in the United ...
Breaking Medicine News(10 mins):